These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22459199)

  • 21. Emerging therapies for advanced gastroenteropancreatic neuroendocrine tumors.
    Gupta S; Engstrom PF; Cohen SJ
    Clin Colorectal Cancer; 2011 Dec; 10(4):298-309. PubMed ID: 21813338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pancreatic neoplasm in 2011: an update.
    Saif MW
    JOP; 2011 Jul; 12(4):316-21. PubMed ID: 21737886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment options for PNET liver metastases: a systematic review.
    Nigri G; Petrucciani N; Debs T; Mangogna LM; Crovetto A; Moschetta G; Persechino R; Aurello P; Ramacciato G
    World J Surg Oncol; 2018 Jul; 16(1):142. PubMed ID: 30007406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Animal models and cell lines of pancreatic neuroendocrine tumors.
    Babu V; Paul N; Yu R
    Pancreas; 2013 Aug; 42(6):912-23. PubMed ID: 23851429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors.
    Wolin EM
    Chemotherapy; 2014; 60(3):143-50. PubMed ID: 25766415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.
    Hauser H; Gerson DS; Reidy-Lagunes D; Raj N
    Curr Treat Options Oncol; 2019 Nov; 20(12):87. PubMed ID: 31776785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    Chamberlain CE; German MS; Yang K; Wang J; VanBrocklin H; Regan M; Shokat KM; Ducker GS; Kim GE; Hann B; Donner DB; Warren RS; Venook AP; Bergsland EK; Lee D; Wang Y; Nakakura EK
    Mol Cancer Ther; 2018 Dec; 17(12):2702-2709. PubMed ID: 30254185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic neuroendocrine tumors: a review.
    Young K; Iyer R; Morganstein D; Chau I; Cunningham D; Starling N
    Future Oncol; 2015; 11(5):853-64. PubMed ID: 25757686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroendocrine tumors of the pancreas.
    Milan SA; Yeo CJ
    Curr Opin Oncol; 2012 Jan; 24(1):46-55. PubMed ID: 22080942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.
    Tachezy M; Zander H; Marx AH; Gebauer F; Rawnaq T; Kaifi JT; Sauter G; Izbicki JR; Bockhorn M
    J Surg Res; 2011 Oct; 170(2):226-32. PubMed ID: 21816425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Neuroendocrine well-differentiated pancreatic tumors].
    Niccoli P
    Rev Prat; 2015 Apr; 65(4):461-5. PubMed ID: 26058180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals].
    Lombard-Bohas C; Cariou B; Vergès B; Coriat R; N'guyen T; François E; Hammel P; Niccoli P; Hentic O
    Bull Cancer; 2014 Feb; 101(2):175-83. PubMed ID: 24557872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endoscopic ultrasound-guided fine-needle aspiration cytology of pancreatic neuroendocrine tumors: a study of 48 cases.
    Chatzipantelis P; Salla C; Konstantinou P; Karoumpalis I; Sakellariou S; Doumani I
    Cancer; 2008 Aug; 114(4):255-62. PubMed ID: 18618505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Pavel ME; Wiedenmann B
    Horm Metab Res; 2011 Nov; 43(12):844-53. PubMed ID: 22105475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is there a role for liver transplantation in metastatic pancreatic neuroendocrine tumors (PNET)?
    Gulati AP; Saif MW
    JOP; 2012 May; 13(3):320-1. PubMed ID: 22572143
    [No Abstract]   [Full Text] [Related]  

  • 36. Pancreatic neuroendocrine tumors.
    Batcher E; Madaj P; Gianoukakis AG
    Endocr Res; 2011; 36(1):35-43. PubMed ID: 21226566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is there a role of radiotherapy in the management of pancreatic neuroendocrine tumors (PNET)?
    Saif MW; Ng J; Chang B; Russo S
    JOP; 2012 Mar; 13(2):174-6. PubMed ID: 22406594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgery in malignant pancreatic neuroendocrine tumors.
    Nguyen SQ; Angel LP; Divino CM; Schluender S; Warner RR
    J Surg Oncol; 2007 Oct; 96(5):397-403. PubMed ID: 17469119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pancreatic neuroendocrine tumors: presentation, management, and outcomes.
    Nissen NN; Kim AS; Yu R; Wolin EM; Friedman ML; Lo SK; Wachsman AM; Colquhoun SD
    Am Surg; 2009 Oct; 75(10):1025-9. PubMed ID: 19886158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.
    Pozzari M; Maisonneuve P; Spada F; Berruti A; Amoroso V; Cella CA; Laffi A; Pellicori S; Bertani E; Fazio N
    Cancer Treat Rev; 2018 Dec; 71():39-46. PubMed ID: 30352319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.